Posted by Michael Wonder on 10 May 2017
Provincial drug plans, including Ontario and BC, make Entyvio (vedolizumab) available to treat inflammatory bowel disease
9 May 2017 - Gut-selective treatment now funded publicly for Canadians with ulcerative colitis and Crohn's disease.
Takeda Canada is pleased to announce that several provinces across Canada including Ontario and British Columbia, have agreed to fund Entyvio (vedolizumab), the first and only gut-selective biologic therapy for inflammatory bowel disease through their public provincial drug plans.
Entyvio is now funded in Ontario and British Columbia for adults with moderate or severe biologic-naïve and biologic-experienced ulcerative colitis or Crohn's disease.
